spacer
home > ebr > summer 2002 > immunotherapy - from suppression to tolerance
PUBLICATIONS
European Biopharmaceutical Review

Immunotherapy - From Suppression to Tolerance

A wide spectrum of diseases can arise if the immune system reacts to antigens and tissues that are better left alone. Allergic reactions to environmental antigens, autoimmune reactions to self tissue antigens, and reactions to allo-antigens in transplants together make up this group of clinical conditions. Current therapies for these diseases either only relieve symptoms, or induce non-specific suppression of the immune system which can lead to severe infection, as well as drug-related toxicity. There is now a resurgence of interest in how the immune system prevents or down-regulates its responses to antigens, leading to the possibility of a new class of treatments for these diseases which addresses antigen-specific tolerance - the 'holy grail' of immunotherapy.

The Immune System - A Two-Sided Coin

The immune system is a powerful and essential defence mechanism which protects against a wide range of potentially damaging invaders - bacteria, viruses and parasites. It maintains constant surveillance over these infectious agents and without it we would not survive for very long. However, there is a price to be paid when it goes wrong and attacks where it should not, resulting in allergies, autoimmune disease and rejection of transplants.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Mark Bodmer, Chief Executive of Lorantis Ltd

Following a PhD in Genetics from Cambridge University in 1982, Dr Mark Bodmer joined Celltech Group plc, where he held a number of research and development roles. From 1994 he served as Director of Biology at Celltech Therapeutics with responsibility for a team of over 100 scientists covering Celltech's biological research, including biology and medicinal chemistry functions.
In 1996 he became the founding CEO of Hexagen, a venture funded genomics start-up company in Cambridge, UK. In September 1998 Hexagen was acquired by Incyte Pharmaceuticals. Mark served as Senior Vice President of R&D for Incyte and President of its European subsidiary until November 1999 when he took up the position of CEO of Lorantis Ltd.

spacer
Dr Mark Bodmer
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera acquires Insight Product Development to strengthen its capabilities

“Every day at Nemera, we work to improve the lives of millions of patients worldwide by designing, developing and manufacturing innovative drug delivery devices. Our vision as a team is to become the most patient-centric drug delivery device company in the industry. We partner closely with our customers to deliver innovative and high quality devices, to ensure that patients will receive the best product and service possible” Marc Hämel, CEO
More info >>

White Papers

Wrap Around Label - A Lot of Content in a Small Space

Faubel & Co. Nachfolger GmbH

One of the world’s largest contract research organizations for the planning and conducting of clinical trials was faced with the challenge of accommodating many different national languages on an inhaler. The inhaler was then to be distributed in 47 countries. Due to the impressive quality and reliable collaboration, the organization commissioned Faubel with finding the optimal labeling solution for the inhaler.
More info >>

 
Industry Events

World Vaccine Congress Europe

28-31 October 2019, Barcelona, Spain

The 20th annual World Vaccine Congress Europe is taking place 28-31 Oct in Barcelona. It’s the biggest and most established European vaccine event with over 250 speakers, 700+ senior vaccine attendees, hundreds of networking hours. It cover key topics across the complete vaccine value chain bringing together: • Government • big pharma • big biotech • SME Biotech • academia and the wider service provider community and their partners to discuss scientific, clinical and strategic advances and opportunities. The event has already confirmed over 200 speakers from Human Vaccine Project, OECD, CEPI, European Commission, FDA, WHO, OECD, NIH, GSK and many more… There is a Super Early Bird offer available – Find Out More www.terrapinn.com/WVCEU/EBR
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement